Visual And Anatomical Outcomes of Pars Plana Vitrectomy in Refractory Diabetic Macular Edema

Purpose:  To find the visual and anatomical outcomes of pars plana vitrectomy in cases of refractory diabetic macular edema. Study Design:  Quasi Experimental study. Place and Duration of Study:  Department of Ophthalmology, Lahore General Hospital from January 2013 to April 2019. Material and Methods:  Seventy-six patients between the age of 18 and 60 years of both genders having refractory diabetic macular edema with macular thickness of 400 micrometers or more on OCT were enrolled. Informed consent was taken. Detailed preoperative workup including visual assessment, examination on slit lamp using 90D or 78D lens for assessment of macular edema and OCT was done. Patients underwent pars plana vitrectomy, ERM, and ILM peeling. Visual assessment and macular thickness was recorded 4 weeks after surgery. Results:  This study included 76 patients with the mean age of 48.15 ± 8.16 years. Patients were further categorized according to age into 2 groups. The gender distribution of patients showed that most of the participants were female in this study.  Mean duration of Diabetes Mellitus was 9.95 ± 6.29 years. Most of the patients did not have previous history of laser and only three patients (3.9%) did not receive Intravitreal Anti-VEGF. Mean preoperative visual acuity was 0.44 ± 0.13 while postoperative visual acuity was 0.876 ± 0.18 (P = 0.000). Similarly, significant decrease in macular thickness was observed after the procedure (P = 0.000). Conclusion:  Pars plana vitrectomy, ERM and ILM peeling can be an effective treatment option for refractory diabetic macular edema.

[1]  K. Bartz-Schmidt,et al.  Interferon Alpha for Refractory Pseudophakic Cystoid Macular Edema (Irvine-Gass Syndrome) , 2020, Ocular immunology and inflammation.

[2]  S. El-Baha,et al.  Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema , 2019, Journal of ophthalmology.

[3]  Lihteh Wu,et al.  Revisiting pars plana vitrectomy in the primary treatment of diabetic macular edema in the era of pharmacological treatment , 2019, Taiwan journal of ophthalmology.

[4]  I. Chatziralli,et al.  Treatment of Macular Edema after Pars Plana Vitrectomy for Idiopathic Epiretinal Membrane Using Intravitreal Dexamethasone Implant: Long-Term Outcomes , 2019, Ophthalmologica.

[5]  P. Stavrakas,et al.  Update in treatment of uveitic macular edema , 2019, Drug design, development and therapy.

[6]  P. McGuire,et al.  Novel therapeutic targets in diabetic macular edema: Beyond VEGF , 2017, Vision Research.

[7]  M. Yaseri,et al.  Outcomes of vitrectomy, membranectomy and internal limiting membrane peeling in patients with refractory diabetic macular edema and non-tractional epiretinal membrane , 2016, Journal of current ophthalmology.

[8]  Shibo Tang,et al.  COMPARISON OF INTRAVITREAL TRIAMCINOLONE ACETONIDE VERSUS INTRAVITREAL BEVACIZUMAB AS THE PRIMARY TREATMENT OF CLINICALLY SIGNIFICANT MACULAR EDEMA , 2015, Retina.

[9]  S. Kang,et al.  Combination of vitrectomy, IVTA, and laser photocoagulation for diabetic macular edema unresponsive to prior treatments; 3-year results , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[10]  M. Yaseri,et al.  Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Refractory Diffuse Diabetic Macular Edema , 2010, Journal of ophthalmic & vision research.

[11]  H. Lemij,et al.  Foveal cone photoreceptor involvement in primary open-angle glaucoma , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  A. Ruby,et al.  Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. , 2005, American journal of ophthalmology.

[13]  Ashraf M. Gad Elkareem,et al.  Outcomes of pars plana vitrectomy for the treatment of persistent diffuse diabetic macular edema , 2018 .

[14]  L. Young,et al.  Current and Emerging Treatment for Diabetic Macular Edema , 2017, International ophthalmology clinics.

[15]  A. Loewenstein,et al.  Diabetic Macular Edema: Emerging Strategies and Treatment Algorithms. , 2017, Developments in ophthalmology.

[16]  Judy E. Kim,et al.  Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. , 2016, JAMA ophthalmology.